-transparent.png){kind=logo}
Phase I studies were conducted in 58 adult cancer patients with Baker's Antifol (BAF), a new active-site directed inhibitor of dihydrofolate reductase. Dose escalation ranged from 10 to 250 mg/m2/day X 5 days and courses of treatment were repeated every 2-3 weeks. Biologic effects were observed mostly at doses greater than 100 mg/m2/day X 5 days. The patients developed myelosuppression during 19% of the trials. Other types of toxicity were dermatitis in 12 to 30% and stomatitis in 7 to 38% of the trials. Toxicity was directly related to the impairment of the patient's liver function. Two partial responses (in a patient with adenocarcinoma of the lung and a patient with transitional cell carcinoma of the bladder) occurred. BAF is an active new chemotherapeutic agent which deserves further clinical trials in patients with various malignancies.
V Rodriguez, and
J Gottlieb, and
M A Burgess, and
R Livingston, and
W Wheeler, and
G Spitzer, and
G P Bodey, and
G R Blumenschein, and
E J Freireich
July 1978,
Biochemical and biophysical research communications,
V Rodriguez, and
J Gottlieb, and
M A Burgess, and
R Livingston, and
W Wheeler, and
G Spitzer, and
G P Bodey, and
G R Blumenschein, and
E J Freireich
January 1978,
Drug metabolism reviews,
V Rodriguez, and
J Gottlieb, and
M A Burgess, and
R Livingston, and
W Wheeler, and
G Spitzer, and
G P Bodey, and
G R Blumenschein, and
E J Freireich
April 1977,
Cancer research,
V Rodriguez, and
J Gottlieb, and
M A Burgess, and
R Livingston, and
W Wheeler, and
G Spitzer, and
G P Bodey, and
G R Blumenschein, and
E J Freireich
February 1982,
American journal of clinical oncology,
V Rodriguez, and
J Gottlieb, and
M A Burgess, and
R Livingston, and
W Wheeler, and
G Spitzer, and
G P Bodey, and
G R Blumenschein, and
E J Freireich
November 1977,
Cancer treatment reports,
V Rodriguez, and
J Gottlieb, and
M A Burgess, and
R Livingston, and
W Wheeler, and
G Spitzer, and
G P Bodey, and
G R Blumenschein, and
E J Freireich
January 1980,
Journal of medicine,
V Rodriguez, and
J Gottlieb, and
M A Burgess, and
R Livingston, and
W Wheeler, and
G Spitzer, and
G P Bodey, and
G R Blumenschein, and
E J Freireich
April 1978,
Cancer treatment reports,
V Rodriguez, and
J Gottlieb, and
M A Burgess, and
R Livingston, and
W Wheeler, and
G Spitzer, and
G P Bodey, and
G R Blumenschein, and
E J Freireich
August 1965,
Cancer chemotherapy reports,
V Rodriguez, and
J Gottlieb, and
M A Burgess, and
R Livingston, and
W Wheeler, and
G Spitzer, and
G P Bodey, and
G R Blumenschein, and
E J Freireich
July 1977,
Cancer,
V Rodriguez, and
J Gottlieb, and
M A Burgess, and
R Livingston, and
W Wheeler, and
G Spitzer, and
G P Bodey, and
G R Blumenschein, and
E J Freireich
January 1983,
Investigational new drugs,
